Abbott India working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

90.40×	74.52×	72.05×	82.00×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
19.54×	19.91×	19.85×	20.65×
106.97×	—	2.04×	2.21×
2.97×	—	89.86×	100.44×
3.02×	1.91×	3.07×	2.94×
1.12×	1.15×	1.20×	1.22×
0.85×	0.72×	1.01×	0.94×
0.70×	0.60×	0.83×	0.74×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ABBOTINDIA₹26,145.00

Abbott India Ltd.

· Pharma & Health

₹ CrorePeersPFIZER GLAXO IPCALAB AJANTPHARM ANTHEM MEDANTA GLENMARK BIOCON

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
Inventory Days (DIO)	82.00	72.05	74.52	90.40
Receivable Days (DSO)	20.65	19.85	19.91	19.54
Payable Days (DPO)	2.21	2.04	—	106.97
Cash Conversion Cycle (days)	100.44	89.86	—	2.97
Working Capital Turnover	2.94	3.07	1.91	3.02
Asset Turnover	1.22	1.20	1.15	1.12
Cash Conversion (CFO/Net Income)	0.94	1.01	0.72	0.85
CFO/EBITDA	0.74	0.83	0.60	0.70

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.